Thursday 15 October 2026
Export IVVD’s income statement to Excel — free account
Invivyd, Inc.
IVVD Healthcare Biotechnology
Invivyd, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $53.4 million, up 110.5% from fiscal 2024. In the quarter to June 2026, revenue grew 21.2%, EPS fell 16.7% and free cash flow fell 226.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
0.67
0.06
+9.84%
Follow IVVD
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '17 | |
|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | — | — | — | — |
P/S ratio |
7.96 | 0.00 | — | — | — | — | — |
Altman Z-Score |
2.85 | (13.19) | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(0.36) | (28.78) | — | — | — | — | — |
Beneish M-Score |
(1.63) | — | — | — | — | — | — |
P/Operating CF |
(27.52) | (1.39) | — | — | — | — | — |
P/B ratio |
1.76 | 0.77 | — | — | — | — | — |
Price to Tangible BV |
1.76 | 0.77 | — | — | — | — | — |
EV/Sales |
3.72 | 0.00 | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.10 | — | — | — | — | — |
EV/Operating CF |
(3.42) | 0.10 | — | — | — | — | — |
EV/FCF |
(3.41) | 0.10 | — | — | — | — | — |
Quick Ratio |
7.04 | 1.29 | 3.99 | 14.88 | 9.53 | 8.80 | — |
Current Ratio |
7.24 | 1.62 | 4.47 | 15.06 | 9.94 | 8.98 | — |
Net Debt/EBITDA |
4.24 | 0.40 | 0.95 | 1.49 | 2.62 | 1.76 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.26 | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
1.11 | 1.00 | 0.87 | 0.91 | 0.81 | 0.22 | — |
Capex/Depreciation |
(0.07) | (0.04) | (0.68) | 1.09 | (0.06) | — | — |
| (33.96%) | (138.71%) | (74.48%) | (52.81%) | (92.05%) | (26.51%) | — | |
| (25.83%) | (94.75%) | (64.88%) | (48.11%) | (61.50%) | (111.29%) | — | |
ROIC |
(233.82%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(24.45%) | (422.56%) | (112.55%) | (68.14%) | (40.88%) | (62.62%) | — |
Average Days of Receivables |
95.09 | 156.82 | — | 0.00 | — | — | — |
Research and Development Expense of Revenue |
71.70% | 540.71% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
125.28% | 249.72% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
21.79% | 77.95% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Graham Net Nets |
0.50 | 0.74 | — | — | — | — | — |
Graham Number |
0.00 | 0.00 | — | — | — | — | — |
Earnings Yield |
(12.96%) | (327.27%) | — | — | — | — | — |
Free Cash Flow Yield |
(13.70%) | (327.10%) | — | — | — | — | — |
Revenue per Share |
0.31 | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(0.34) | (1.44) | (1.58) | (2.03) | (4.33) | (4.04) | — |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.02) | 0.00 | 0.00 | — |
Free Cash Flow per Share |
(0.34) | (1.44) | (1.59) | (2.05) | (4.34) | (4.04) | — |
Cash per Share |
1.32 | 0.59 | 1.83 | 3.44 | 13.88 | 31.87 | — |
Shareholders Equity per Share |
1.40 | 0.57 | 1.62 | 3.29 | 13.09 | (18.08) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
1.40 | 0.57 | 1.62 | 3.29 | 13.09 | (18.08) | — |
Free Cash Flow |
(58.29) | (170.63) | (173.78) | (221.69) | (184.82) | (14.57) | — |
Working Capital |
213.30 | 38.71 | 174.59 | 351.89 | 554.65 | 104.31 | — |
Capital Expenditures |
(0.15) | (0.14) | (0.61) | (1.70) | (0.08) | — | — |
Net Current Asset Value |
212.12 | 38.71 | 173.17 | 349.72 | 554.64 | (65.25) | — |
EV/EBIT |
0.00 | 0.10 | — | — | — | — | — |
Capex to Sales |
0.00 | 0.01 | 0.00 | 0.00 | 0.00 | — | — |
Price to Operating Income |
0.00 | 0.00 | — | — | — | — | — |
| Other line items | |||||||
Depreciation/Fixed assets |
1.54 | 2.06 | 0.48 | (0.68) | 17.24 | — | — |
Cash ROIC |
(12.45%) | (124.65%) | (45.96%) | (30.45%) | (16.08%) | (29.29%) | — |
Accounts Receivable Turnover |
4.30 | 4.50 | — | — | — | — | — |
Accounts Payable Turnover |
0.31 | 0.18 | 0.00 | 0.13 | 0.00 | 0.00 | — |
Inventory Turnover |
0.00 | 0.00 | — | 0.00 | 0.00 | — | — |
Average Days of Payables |
1,338.82 | 2,356.93 | 0.00 | 1,198.50 | 2,110,795.00 | 0.00 | — |
Days of Inventory on Hand |
0.00 | 0.00 | — | 0.00 | 0.00 | — | — |
Average Receivables |
12.41 | 5.64 | — | — | — | — | — |
Average Payables |
12.10 | 9.20 | 4.74 | 3.65 | 6.97 | 6.97 | — |
Average Assets |
203.20 | 179.35 | 306.17 | 501.63 | 368.74 | 58.69 | — |
Average Common Equity |
154.54 | 122.50 | 266.72 | 456.99 | 246.39 | 246.39 | — |
Columns are period end dates